@article{article_1747406, title={Potential role of serum prolidase as a biomarker in predicting pressure ulcers among palliative care patients}, journal={Journal of Medicine and Palliative Care}, volume={6}, pages={487–490}, year={2025}, author={Başpınar, Osman and Avcı, Deniz and Şimşek, Yasin and Uçan, Anıl and Koçer, Derya and Dizdar, Oğuzhan Sıtkı}, keywords={prolidaz, bası ülseri, C-reaktif protein, palyatif bakım, prokalsitonin}, abstract={Aims: Prolidase is a marker that plays a role in inflammation, collagen turnover, tissue damage, wound healing and many similar conditions. Pressure ulcers (PU) are common among palliative care patients and increase morbidity and mortality. Predicting the severity of PU is very important for follow-up and treatment. It is possible that the association of prolidase with such wounds will provide clinical benefit. Methods: The prospective cross-sectional study included 76 hospitalized patients in a palliative care unit between 2019 and 2020. Patients were divided into two groups: with PU and without PU (controls). PU patients were classified into mild (stages I–II) and severe (stages III–IV). Serum prolidase level, C-reactive protein (CRP), and procalcitonin were measured. Results: Patients with PU had significantly higher prolidase and CRP levels compared with controls. Severe PU patients had higher prolidase and CRP than mild PU patients. Procalcitonin levels were low and similar across groups. A positive correlation was found between prolidase, CRP, and PU severity. Conclusion: Serum prolidase level may be a useful biomarker reflecting PU severity in palliative care patients. Further largescale prospective studies are needed.}, number={5}, publisher={MediHealth Academy Yayıncılık}, organization={none}